Charles Schwab
BLPH

Charles Schwab’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Charles Schwab’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,562
Closed -$91K – 3558
2020
Q4 		$91K Hold
13,562
– – ﹤0.01% 3325
2020
Q3 		$139K Buy
13,562
+1,976
+17% +$23.2K ﹤0.01% 3227
2020
Q2 		$146K Buy
+11,586
New +$162K ﹤0.01% 3210

Other funds holding BLPH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab's BLPH Position: Q1 2021 in Review

Charles Schwab sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q1 2021, closing a stake of 13,562 shares — an estimated $91K sold.

Charles Schwab first reported a position in BLPH in Q2 2020 and held it in 3 quarters. The position peaked at $146K in Q2 2020. 39 funds tracked by Wall St. Rank hold BLPH as of Q1 2021.

  • Charles Schwab reported no remaining Bellerophon Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Charles Schwab sold 13,562 Bellerophon Therapeutics, Inc. shares in Q1 2021, an estimated $91K.
  • Charles Schwab first reported a position in Bellerophon Therapeutics, Inc. in Q2 2020 and held it in 3 quarters.
  • Charles Schwab's Bellerophon Therapeutics, Inc. position peaked at $146K in Q2 2020.
  • 39 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q1 2021.

Based on Charles Schwab's 13F filing for Q1 2021, filed 17 May 2021.